Generic Ozempic Is Here in Canada — But Don't Expect a 50% Price Drop Just Yet

On Tuesday, April 28, 2026, Health Canada quietly made history. It approved the country's first generic version of semaglutide — the active ingredient in Ozempic — making Canada the first G7 nation to authorize a generic of the world's best-selling diabetes drug.

The approval went to Dr. Reddy's Laboratories, an Indian generics manufacturer that already sells the same drug in India under the brand name Obeda. Health Canada cleared it for the same indication as brand Ozempic: once-weekly treatment of Type 2 diabetes in adults.

For the more than one million Canadians currently taking semaglutide — and the hundreds of thousands more priced out of it — this is the news they've been waiting on for years. But the price relief that actually shows up in your pharmacy is going to look different than the headlines suggest. Here's why.

The 35% number — and why you won't see it yet

The savings story spreading online runs something like: "Generics are 45 to 90% cheaper than brand drugs. Get ready to pay a fraction!"

That's directionally right, but for a single approval like this one, the math is governed by a formal agreement called the pan-Canadian Pharmaceutical Alliance (pCPA) — a framework that public and private drug plans use to set generic pricing in lockstep. Under that framework:

• One generic on the market: Priced at 75–85% of the brand list price.
• Two generics: Both drop to roughly 50% of brand.
• Three or more generics: Price collapses to about 35% of brand.

Today, with just Dr. Reddy's approved, we're at step one. Brand Ozempic's list price in Canada is currently $228 for a four-week supply, before pharmacy and distributor markups. So the first generic should land somewhere in the $170–$195 range at list — meaningful, but a long way from the half-price-or-less story most people are anticipating.

The good news: Health Canada is currently reviewing eight other generic semaglutide submissions. As soon as a second one clears, prices for both drop. A third pushes the whole category to roughly 35% of where Ozempic sits today.

When does this actually hit pharmacies?

Approval and availability are not the same thing. Dr. Reddy's still needs to ship product into Canada, distributors need to stock it, and pharmacies need to start dispensing. Generics often take weeks to months to physically appear on shelves after a Health Canada drug identification number (DIN) is assigned.

We'll be tracking pharmacy-by-pharmacy availability on glp1prices.ca and updating prices as soon as the generic lands at major chains and independents.

The weight-loss caveat

This is important, and it gets glossed over in a lot of the coverage: Health Canada approved generic semaglutide for Type 2 diabetes only. Not for weight management.

That's the same regulatory situation as brand Ozempic — Wegovy is the version with a weight-loss indication. In practice, many Canadians use Ozempic off-label for weight loss with a prescription from a willing physician. Generic semaglutide will be used the same way.

What this means for coverage: most public and private drug plans only reimburse semaglutide when it's prescribed for diabetes. If you're using it for weight loss, you've been paying out of pocket — and you'll continue to pay out of pocket for the generic, just at a lower number.

Why Canada beat the US, the UK, and the EU to this

Patent law. Novo Nordisk's semaglutide patents expire on different dates in different countries. In Canada, the relevant patent lapsed earlier this year — generic versions became technically legal as of January 2026 — and Health Canada took roughly four months from that point to clear the first submission.

In the United States, Novo Nordisk's patents extend further into the decade, so the FDA can't approve a generic even if a manufacturer files one. The same is broadly true across the EU, the UK, and Japan. India's patent expired earlier still, which is why Dr. Reddy's already had a finished, approved product ready to bring to market the moment Canadian regulators were willing to look at it.

That's why the "first G7 country" headline matters: Canada isn't doing anything regulatory that's faster or more permissive than its peers. It's just first in line on the patent calendar.

What to do right now

If you're currently paying for Ozempic out of pocket:

1. Don't switch yet. The generic isn't on shelves. Stay on your current supply.
2. Talk to your prescriber about whether they'll write for generic semaglutide once it's available. Most will. Some patients prefer to stay on brand for consistency reasons; that's a legitimate conversation to have.
3. Check your insurance coverage language. Some plans automatically default to the cheapest available equivalent. Others require a prescriber note.
4. Watch pricing on glp1prices.ca. We'll update the Ozempic listings as soon as generic prices appear at Canadian pharmacies.

If you're new to semaglutide and the cost has been the barrier, the timing is finally turning in your favour — but be realistic. The deepest discounts are still a few generic approvals away. The next twelve to eighteen months are when the real shift happens.

The bottom line

Canada becoming the first G7 country to approve generic Ozempic is a genuine milestone, especially considering Ozempic was Canada's best-selling drug in 2025 with $2.9 billion in sales. But this is the start of a phased price drop, not an instant one. Expect modest savings now, meaningful savings as the second and third generics clear, and a fundamentally different cost structure for semaglutide by the end of 2027.

We'll keep this post updated as more approvals come in and as real pharmacy prices start landing.